Bayer: encouraging new data on aflibercept

(CercleFinance.com) - Bayer announced on Tuesday that a Phase III study of a new mode of administration for its treatment of central retinal vein occlusion (CRVO) with macular edema had met its primary endpoint.


The trial - conducted over a 36-week period - confirmed the non-inferiority of aflibercept 8 mg administered every eight weeks compared with the current 2 mg version with injections every four weeks.

For patients, this means less frequent injections for a comparable level of efficacy and safety", explains the laboratory in a press release.

Bayer is developing aflibercept in collaboration with the American Regeneron, which holds the rights to the drug in the USA, while the German group holds marketing rights outside the US market.

Aflibercept has already been approved in around 100 countries for a number of indications, including neovascular (wet) age-related macular degeneration (AMD).

Copyright (c) 2024 CercleFinance.com. All rights reserved.